C4 Therapeutics, Inc.: cashflow_investing
| Value | {"amount": -136284000, "concept": "us-gaap:NetCashProvidedByUsedInInvestingActivities", "currency": "USD"} |
|---|---|
| Period | 2020-01-01 – 2020-09-30 |
| Status | superseded |
| Entity | C4 Therapeutics, Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T17:06:02.697479+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/f910d88b-a7c4-40e1-8966-989cf6d55b27
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001564590-20-053604Retrieved: 2026-08-19T17:06:02.697479+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001662579/cashflow-investing/2020-09-30 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/f910d88b-a7c4-40e1-8966-989cf6d55b27
History
- no predecessors — first report